Coya Therapeutics Begins Blinded Extension Phase of ALSTARS Trial for COYA 302 in ALS
HOUSTON, Texas, June 8, 2026 Coya Therapeutics, Inc. announced a significant milestone in the ongoing ALSTARS clinical trial, with...
Clinical Trials for New Therapy
Corsair Pharma Showcases Positive Phase 1 TRX-248 Data at PHA 2026
NEWARK, Calif., June 8, 2026 Corsair Pharma, Inc. announced three presentations showcasing positive Phase 1 clinical data for its...
Novo Nordisk’s CagriSema Delivers Strong HbA1c and Weight Loss Results in Phase 3 REIMAGINE Trials
Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026 Novo Nordisk has unveiled compelling Phase 3 clinical data for...
Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Novo Nordisk’s CagriSema Delivers Superior Diabetes Control
PLAINSBORO, New Jersey and BAGSVÆRD, Denmark, June 7, 2026 Novo Nordisk has reported compelling Phase 3 results demonstrating that...
Altesa’s Vapendavir Shows Promise in Preventing COPD Flares
WASHINGTON, D.C., June 5, 2026 Altesa BioSciences has unveiled encouraging new Phase 2 clinical findings demonstrating that vapendavir, its...
Teva Reports Real-World Benefits of AUSTEDO for Huntington’s Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
Rivus Highlights RV-8451 Muscle-Preserving Obesity Data
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 5, 2026 Rivus Pharmaceuticals announced new preclinical data for RV-8451, its...
Shattuck Labs to Present Phase 1 Data for SL-325 on June 8
AUSTIN, Texas and DURHAM, N.C., June 5, 2026 Shattuck Labs announced that it will host an investor call and...
Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...